Longevity & AgingPartial Reprogramming Pushes Cellular Aging Backward, but Clinical Hurdles Remain
This review from Mayo Clinic's Kogod Center on Aging examines reprogramming-induced rejuvenation (RIR), an approach that briefly activates early reprogramming programs in cells without erasing their identity. The authors survey new delivery tools beyond classic Yamanaka factors, including mRNA, CRISPR activation, and chemical cocktails, along with screening platforms that search for safer rejuvenation factors. They describe reports of functional improvement in brain, liver, intestine, cardiovascular, and epithelial tissues, linked to reduced senescence, less DNA damage, younger epigenetic age, and better regeneration. Major obstacles remain: narrow therapeutic windows, incomplete understanding of mechanisms, and a lack of standardized biomarkers. The authors suggest single-cell technologies, computational prediction, and systematic in vivo testing could move RIR toward therapies for age-related disease. This is a review, not a new clinical study, and it does not establish human benefit.
